Published in Arthritis Rheum on November 01, 1997
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases | NCT04922736
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med (2007) 2.86
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol (2011) 1.71
Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res (Hoboken) (2011) 1.67
Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine. J Rheumatol (2009) 1.42
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis (2007) 1.27
Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis (2007) 1.26
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood (2002) 1.26
Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol (2004) 1.18
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis (2007) 1.15
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum (2008) 1.15
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2012) 1.13
Assessing body image in patients with systemic sclerosis (scleroderma): validation of the adapted Satisfaction with Appearance Scale. Body Image (2007) 0.97
Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale. Ann Rheum Dis (2007) 0.95
Psychiatric symptoms and quality of life in systemic sclerosis. Clin Pract Epidemiol Ment Health (2012) 0.95
The Italian version of the Mouth Handicap in Systemic Sclerosis scale (MHISS) is valid, reliable and useful in assessing oral health-related quality of life (OHRQoL) in systemic sclerosis (SSc) patients. Rheumatol Int (2011) 0.94
[Patient-centered assessment of functional health in systemic sclerosis -- where are we now?]. Z Rheumatol (2004) 0.93
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clin Cancer Res (2015) 0.92
Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol (2006) 0.91
Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology (Oxford) (2008) 0.91
Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients. Neurogastroenterol Motil (2009) 0.89
The correlation between durometer score and modified Rodnan skin score in systemic sclerosis. Rheumatol Int (2011) 0.88
Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores. Open Rheumatol J (2008) 0.87
Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial. Ann Rheum Dis (2013) 0.86
Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. Clin Rheumatol (2013) 0.85
Pressure and pain in systemic sclerosis/scleroderma--an evaluation of a simple intervention (PISCES): randomised controlled trial protocol. BMC Musculoskelet Disord (2012) 0.84
Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Curr Rheumatol Rev (2010) 0.82
Valuation of scleroderma and psoriatic arthritis health states by the general public. Health Qual Life Outcomes (2010) 0.82
Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis. Clin Exp Rheumatol (2010) 0.82
The scleroderma Assessment Questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis. Z Rheumatol (2006) 0.81
My approach to the treatment of scleroderma. Mayo Clin Proc (2013) 0.81
Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol (2004) 0.81
Lidocaine for systemic sclerosis: a double-blind randomized clinical trial. Orphanet J Rare Dis (2011) 0.81
A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index. Rheumatology (Oxford) (2008) 0.81
What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). Rheumatol Int (2009) 0.80
Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. Health Qual Life Outcomes (2013) 0.79
Use of the Patient-generated Index in systemic sclerosis to assess patient-centered outcomes. J Rheumatol (2013) 0.79
Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools. Clin Rheumatol (2012) 0.79
Predictors of fatigue severity in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. PLoS One (2011) 0.79
Lower limb muscle strength is associated with functional performance and quality of life in patients with systemic sclerosis. Braz J Phys Ther (2015) 0.79
Depression among the Moroccan systemic sclerosis. Clin Rheumatol (2011) 0.78
Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. Clin Rheumatol (2013) 0.78
Pain-related diseases and sleep disorders. Braz J Med Biol Res (2012) 0.78
Are scores on English and French versions of the PHQ-9 comparable? An assessment of differential item functioning. PLoS One (2012) 0.77
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis (2017) 0.77
Anti-Interferon-Inducible Protein 16 Antibodies Associate With Digital Gangrene in Patients With Scleroderma. Arthritis Rheumatol (2016) 0.76
Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial. Arthritis Res Ther (2015) 0.76
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open (2016) 0.75
Platelet gel in the treatment of severe scleroderma skin ulcers. Rheumatol Int (2011) 0.75
Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) (2015) 0.75
No evidence for a role of the proximal IL-6 G/C -174 single nucleotide polymorphism in Italian patients with systemic sclerosis. J Cell Mol Med (2007) 0.75
Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Curr Respir Med Rev (2016) 0.75
Management of Musculoskeletal Involvement in Systemic Sclerosis. Curr Treatm Opt Rheumatol (2016) 0.75
Improvement of Mouth Functional Disability in Systemic Sclerosis Patients over One Year in a Trial of Fat Transplantation versus Adipose-Derived Stromal Cells. Stem Cells Int (2016) 0.75
Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis. J Rheumatol (2014) 0.75
Cross-cultural adaptation and validation of the Brazilian version of the Scleroderma Health Assessment Questionnaire (SHAQ). Clin Rheumatol (2013) 0.75
Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis. Clin Rheumatol (2016) 0.75
Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients. Clin Exp Med (2015) 0.75
[Medico-legal assessment of systemic sclerosis]. Z Rheumatol (2007) 0.75
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (1997) 6.10
Criteria for the classification of early systemic sclerosis. J Rheumatol (2001) 5.39
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07
Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1994) 3.24
Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum (2000) 3.02
Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum (1988) 2.93
Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol (1989) 2.67
Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum (1994) 2.41
Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum (1995) 2.38
Long-term outcomes of scleroderma renal crisis. Ann Intern Med (2000) 2.27
Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum (1984) 2.17
Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum (1980) 2.13
Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum (1994) 2.11
Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum (1987) 2.11
Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med (1990) 2.03
Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol (1979) 2.02
Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med (1971) 2.00
The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol (1998) 1.97
Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum (2000) 1.97
Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol (1993) 1.96
Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum (1991) 1.94
Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med (1971) 1.93
Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med (1993) 1.91
D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med (1982) 1.84
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum (2000) 1.82
Carpal arthritis with ankylosis in late onset Still's disease. Arthritis Rheum (1976) 1.82
The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum (1997) 1.78
Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum (1995) 1.78
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum (1999) 1.75
Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum (1986) 1.72
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis (2006) 1.70
A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum (1982) 1.62
Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum (1988) 1.54
Palmar fasciitis and polyarthritis associated with ovarian carcinoma. Ann Intern Med (1982) 1.51
A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum (1982) 1.51
The epidemiology of polymyositis. Am J Med (1970) 1.50
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med (1994) 1.50
The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis. Ann Intern Med (1967) 1.45
Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum (1999) 1.45
Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum (1998) 1.45
Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum (1985) 1.45
Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) (1983) 1.44
Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum (1985) 1.42
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum (2001) 1.42
Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum (1971) 1.40
Photopheresis for scleroderma? No! J Rheumatol (1992) 1.40
D-penicillamine in the treatment of localized scleroderma. Arch Dermatol (1990) 1.39
Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol (1990) 1.37
A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol (1990) 1.35
Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum (1984) 1.35
Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum (1992) 1.33
Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum (2001) 1.31
The rheumatic manifestaions of progressive systemic sclerosis (scleroderma). Clin Orthop Relat Res (1968) 1.30
Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum (1984) 1.30
Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med (1987) 1.26
Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med (1984) 1.26
Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med (1984) 1.26
Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis (1973) 1.24
Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum (1992) 1.23
Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am (1990) 1.23
Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren's syndrome. Ann Neurol (1986) 1.22
Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum (1985) 1.21
Herpes zoster in systemic lupus erythematosus. J Rheumatol (1995) 1.21
Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum (1968) 1.17
Anemia and scleroderma: frequency, causes, and marrow findings. Arch Intern Med (1968) 1.17
Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum (1999) 1.16
Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum (1997) 1.14
Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum (1994) 1.13
Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J (1993) 1.12
Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. Arch Dermatol (1987) 1.11
The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med (1986) 1.11
Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol (1997) 1.10
Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum (2000) 1.09
Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III. J Clin Invest (1993) 1.08
Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum (1992) 1.07
Anti-SS-A antibodies and fetal outcome in maternal systemic lupus erythematosus. Arthritis Rheum (1986) 1.07
Normotensive renal failure in systemic sclerosis. Arthritis Rheum (1989) 1.06
Tryptophan-induced eosinophilia-myalgia syndrome. N Engl J Med (1990) 1.06
Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med (1988) 1.05
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum (1998) 1.05
Lack of association between augmentation mammoplasty and systemic sclerosis (scleroderma). Arthritis Rheum (1996) 1.04
Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum (1990) 1.03
Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest (1983) 1.03
Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol (1996) 1.03
Systemic sclerosis secondary to occupational exposure. Am J Med (1988) 1.02
Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature. Arthritis Rheum (1991) 1.02
Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum (1996) 1.01
Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. Lupus (1995) 1.01
Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med (1986) 0.99
Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol (1995) 0.98
Thyroid disease in progressive systemic sclerosis: increased frequency of glandular fibrosis and hypothyroidism. Ann Intern Med (1981) 0.98
A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum (1990) 0.98
Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum (1988) 0.98
Vasculitis in systemic sclerosis: association with Sjögren's syndrome and the CREST syndrome variant. J Rheumatol (1987) 0.98
Fertility and pregnancy outcome in women with systemic sclerosis. Arthritis Rheum (1999) 0.98
A controlled study of the long-term prognosis of adult Still's disease. Am J Med (1995) 0.97
Conclusion and identification of the core set of variables to be used in clinical investigations. Clin Exp Rheumatol (2003) 0.96
Novel human autoantibodies reactive with 5'-terminal trimethylguanosine cap structures of U small nuclear RNA. J Immunol (1992) 0.96
Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol (1985) 0.96